TERAPÉUTICA CON ANTICUERPOS MONOCLONALES EN LA ENFERMEDAD DE ALZHEIMER

Abstract

Introduction: Alzheimer's disease is a slow and progressive neurodegenerative pathology, characterised by cognitive impairment and decreased independence in daily personal activities. Objective: To identify the main advances made in the last 5 years in monoclonal antibody therapy in the treatment of Alzheimer's disease. Methodology: This is a systematic review based on a search of studies, trials and meta-analyses using Google and Google Scholar search engines and through national and international databases such as: BVS, Dialnet, Medline, Scielo and Elsevier, Mediagraphic, Springer, Scopus. Results: When using monoclonal antibodies as a therapeutic option, there is no evidence of significant changes either at the beginning or in the advanced disease process and further studies are needed to establish their use, however, it is clear that monoclonal antibodies against Aβ can indeed improve activities of daily living. Conclusions: Due to the limited number of available trials, statistical significance was only found for bapineuzumab, an antibody directed against the N-terminus of Aβ. It not only demonstrated an ability to improve cognition and function, but also showed improvements in activities of daily living in terms of efficacy. However, it is important to note that bapineuzumab administration was associated with the occurrence of serious adverse events and requires further analysis when recommending its use.